Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2020 Mar 4;10(3):29. doi: 10.1038/s41408-020-0286-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Incidence of VOD/SOS after defibrotide prophylaxis (a) and proportion of patients with successful outcomes with defibrotide treatment (b) in patients with prior GO exposure. This figure shows the incidence of VOD/SOS in patients receiving defibrotide prophylaxis after GO exposure in the overall analysis and congress report, along with the efficacy of defibrotide in patients with VOD/SOS after GO exposure in the overall analysis and in patients with VOD/SOS receiving defibrotide in the phase 2, dose-finding study with and without GO exposure. VOD/SOS veno-occlusive disease/sinusoidal obstruction syndrome, GO gemtuzumab ozogamicin. ^aThe congress report was analyzed separately from the PubMed search²². ^bA phase 2, dose-finding study investigating defibrotide in VOD/SOS patients post-HCT included 20 (74%) of the 27 patients identified in the overall analysis as receiving defibrotide for VOD/SOS¹⁵.